ArticleFrontiers in immunology2022
EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Prediction models for CAR-T Cell therapy-related adverse events in hematologic malignancies: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma.Journal of cancer research and clinical oncology · 2025Pooled it
- Predictive Models for Toxicities after CAR T-cell Therapy: Challenges and Opportunities.Blood cancer discovery · 2026Review
- Biomarkers of Endothelial Damage in Acute Graft-Versus-Host Disease After Allogenic Hematopoietic Stem Cell Transplantation: Methodological Challenges.Journal of clinical laboratory analysis · 2026Review
- Preinfusion risk factors for the development of severe neurotoxicity following CART therapy in pediatric patients.HemaSphere · 2026Article
- Haemostatic changes during CART cell therapy and risk of complications.Cancer immunology, immunotherapy : CII · 2026Article
- Donor-derived CD19-targeted CAR-NK cells induce complete remission in a child with relapsed B-ALL after failure of blinatumomab and autologous CD19-targeted CAR-T.Journal for immunotherapy of cancer · 2026Article
- Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact.Bone marrow transplantation · 2026Article
- Neurotoxicity of Immunotherapy: Immune Checkpoint Inhibitor-Related Encephalitis vs. Immune Effector Cell-Associated Neurotoxicity Syndrome.World journal of oncology · 2026Review
- New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma.Blood advances · 2026Article
- Endotheliopathy in CAR T-Cell Therapy: Mechanistic Insights into the VWF/ADAMTS13 Axis and the Angiopoietin-Tie2 Pathway.TH open : companion journal to thrombosis and haemostasis · 2026Review
- Repurposing mitochondrial-targeting drugs for management of ICANS in CAR T-cell therapy: a novel steroid-sparing approach.Frontiers in pharmacology · 2026Article
- Reversible cerebral vasoconstriction syndrome following ciltacabtagene autoleucel therapy for relapsed multiple myeloma: a case report.Frontiers in immunology · 2026Article
- [Chimeric antigen receptor T-cells for patients with hematologic malignancies].Zeitschrift fur Rheumatologie · 2025Review
- Blood proteomics for quantitative biomarkers of cellular therapies.Biomarker research · 2025Review
- Targeting synergetic endothelial inflammation by inhibiting NFKB and JAK-STAT pathways.iScience · 2025Article
- Review
- Predictive Power of Baseline [Diagnostics (Basel, Switzerland) · 2025Article
- Endothelial Activation and Stress Index Is Associated With Adverse Maternal and Perinatal Outcomes in Preeclampsia.Journal of the American Heart Association · 2025Article
- Classification of patients with relapsed/refractory large B-cell lymphoma who do not develop early CRS/NE toxicity using ZUMA clinical trial data.Journal for immunotherapy of cancer · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endothelial dysfunction is associated with two main complications of chimeric antigen receptor T (CAR-T) cell therapy, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). This study evaluates the Endothelial Activation and Stress Index (EASIX) as a prognostic marker for high-grade CRS and ICANS in patients treated with CD19-directed CAR-T cells. Methods: In this retrospective study, a training cohort of 93 patients from the ZUMA-1 trial and a validation cohort of 121 patients from two independent centers (University Hospital Heidelberg, Charité University Medicine Berlin) were investigated. The primary objective was to assess the predictive capacity of EASIX measured immediately before the start of lymphodepletion (EASIX-pre) for the occurrence of grade ≥3 CRS and/or ICANS. To explore a possible endothelial link, serum levels of endothelial stress markers (angiopoietin-2, suppressor of tumorigenicity-2, soluble thrombomodulin, and interleukin-8) were determined before lymphodepletion and on day 7 after CART infusion in the validation cohort ( Results: The prognostic effect of EASIX-pre on grade ≥3 CRS and/or ICANS was significant in the training cohort [OR 2-fold increase 1.72 (1.26-2.46)] and validated in the independent cohort. An EASIX-pre cutoff >4.67 derived from the training cohort associated with a 4.3-fold increased odds ratio of severe CRS/ICANS in the independent cohort. Serum endothelial distress markers measured on day+7 correlated with EASIX-pre and associated with severe complications. Conclusions: EASIX-pre is a powerful predictor of severe CRS/ICANS after CD19-directed CART therapy and might be used as a basis for risk-adapted prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.